The Bulk Drugs Manufacturers Association of India (BDMAI) has unanimously elected Shri Ch. A.P. Rameswara Rao, Chief Promoter & Director of the Rakshit Group of Companies, as its National President.
With over 35 years of expertise in manufacturing bulk drugs and APIs, Shri Rameswara Rao has significantly contributed to the growth of India’s pharmaceutical sector. He began his career at Vorin Labs (later acquired by Mylan Laboratories), pioneering innovations and playing a key role in the development of Ciprofloxacin HCl.
Entrepreneurial Leadership
Shri Rameswara Rao embarked on his entrepreneurial journey in 1996 with Metrochem Industries. He later founded multiple successful ventures, including:
- Rakshit Drugs
- Sainor Laboratories
- Azico Biophore
Under his leadership, these companies generate a combined turnover exceeding USD 120 million, employ over 2,000 professionals, and produce a diverse portfolio of APIs for both domestic and regulated global markets.
Shri Rameswara Rao is recognized as a soft-spoken yet decisive leader, admired for his vision, humility, and firm decision-making.
About BDMAI
Established in 1991, the BDMAI represents India’s bulk drug and API manufacturers, with objectives including:
- Strengthening India’s self-reliance in APIs and reducing import dependency
- Promoting global quality standards and compliance
- Advocating policy reforms with government and regulatory bodies
- Supporting sustainable growth through innovation, R&D, and environmental responsibility
His appointment comes at a crucial time as India aims to consolidate its position as a global pharmaceutical hub, ensuring affordable, high-quality, and secure bulk drug supply.
Shri Ch. A.P. Rameswara Rao New Leadership
The BDMAI expressed confidence that under Shri Rameswara Rao’s leadership, the association will:
- Scale new heights in policy advocacy and industry growth
- Enhance India’s global healthcare presence
- Continue promoting innovation, sustainability, and quality standards across the bulk drug and API sectors
Shri Rameswara Rao’s leadership is expected to strengthen India’s pharmaceutical ecosystem, supporting domestic manufacturers and enhancing international competitiveness.
